Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)

Latest News

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three indices closed the day in record territory.

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Monday's trending topics.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's plans to acquire Juno Therapeutics for about $9 billion on Monday.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

The Government Shutdown May Actually Be a Positive for the Stock Market

The Government Shutdown May Actually Be a Positive for the Stock Market

There are 5 key factors that will impact stocks this week.

M&A Rumors Rise Again

About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

A Pause That Refreshes, Not a Signal to Be Bearish on Market

A Pause That Refreshes, Not a Signal to Be Bearish on Market

The bears may sound smart, but they remain toothless.

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin maintains its decline while U.S. stock futures suggest a rebound from yesterday's small loss. Are you ready for today's trading?

Juno Therapeutics Has a Great Setup

Juno Therapeutics Has a Great Setup

Institutions are piling into Juno Therapeutics.

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

Price Momentum Still the Key, as Tax Reform and the Fed Are Ignored

There are some signs of selling into the strength especially in technology names.

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor

I've cut a few positions and haven't made any notable buys today.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.